JP2015516949A - オステオポンチンとカルシウムおよび/またはストロンチウム含有粒子とを含有するナノ粒子凝集体 - Google Patents

オステオポンチンとカルシウムおよび/またはストロンチウム含有粒子とを含有するナノ粒子凝集体 Download PDF

Info

Publication number
JP2015516949A
JP2015516949A JP2015502339A JP2015502339A JP2015516949A JP 2015516949 A JP2015516949 A JP 2015516949A JP 2015502339 A JP2015502339 A JP 2015502339A JP 2015502339 A JP2015502339 A JP 2015502339A JP 2015516949 A JP2015516949 A JP 2015516949A
Authority
JP
Japan
Prior art keywords
opn
species
biofilm
nanoparticle aggregate
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015502339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516949A5 (cg-RX-API-DMAC7.html
Inventor
ビルケダル,ヘンリク
オルセン,ヤコブ
スコフゴード,ヨナス
シュラファー,セバスティアン
ルイーズ マイア,リッケ
ルイーズ マイア,リッケ
ニュヴァド,ベンテ
スチュアート サザーランド,ダンカン
スチュアート サザーランド,ダンカン
ラングボー ヴェイス,ペータ
ラングボー ヴェイス,ペータ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arla Foods AMBA
Original Assignee
Arla Foods AMBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arla Foods AMBA filed Critical Arla Foods AMBA
Publication of JP2015516949A publication Critical patent/JP2015516949A/ja
Publication of JP2015516949A5 publication Critical patent/JP2015516949A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A61K8/0275—Containing agglomerated particulates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
JP2015502339A 2012-03-28 2013-03-27 オステオポンチンとカルシウムおよび/またはストロンチウム含有粒子とを含有するナノ粒子凝集体 Pending JP2015516949A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12161802.9 2012-03-28
EP12161802 2012-03-28
PCT/EP2013/056598 WO2013144247A1 (en) 2012-03-28 2013-03-27 Nanoparticle aggregates containing osteopontin and calcium- and/or strontium-containing particles

Publications (2)

Publication Number Publication Date
JP2015516949A true JP2015516949A (ja) 2015-06-18
JP2015516949A5 JP2015516949A5 (cg-RX-API-DMAC7.html) 2016-06-02

Family

ID=48141914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015502339A Pending JP2015516949A (ja) 2012-03-28 2013-03-27 オステオポンチンとカルシウムおよび/またはストロンチウム含有粒子とを含有するナノ粒子凝集体

Country Status (13)

Country Link
US (2) US20150044260A1 (cg-RX-API-DMAC7.html)
EP (1) EP2830647A1 (cg-RX-API-DMAC7.html)
JP (1) JP2015516949A (cg-RX-API-DMAC7.html)
KR (1) KR20150004814A (cg-RX-API-DMAC7.html)
CN (1) CN104321073A (cg-RX-API-DMAC7.html)
AR (1) AR090569A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013241750A1 (cg-RX-API-DMAC7.html)
CA (1) CA2868684A1 (cg-RX-API-DMAC7.html)
CL (1) CL2014002583A1 (cg-RX-API-DMAC7.html)
EA (1) EA201491691A1 (cg-RX-API-DMAC7.html)
MX (1) MX2014011594A (cg-RX-API-DMAC7.html)
NZ (1) NZ700295A (cg-RX-API-DMAC7.html)
WO (1) WO2013144247A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021193398A1 (cg-RX-API-DMAC7.html) * 2020-03-27 2021-09-30

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
US12109284B2 (en) 2016-11-08 2024-10-08 Dentherapy Ltd Compositions comprising fluoride and calcium and method for preparing them
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020197887A1 (en) * 2019-03-22 2020-10-01 The Board Of Regents Of The University Of Oklahoma Surface-modified doped titanium dioxide nanoparticles and uses
CN111366733B (zh) * 2020-03-07 2022-02-08 浙江大学 骨桥蛋白作为靶分子在调节肠道菌群定植中的应用
GB202010987D0 (en) 2020-07-16 2020-09-02 Dentherapy Ltd Oral care compositions and methods
GB202110114D0 (en) 2021-07-14 2021-08-25 Dentherapy Ltd Oral care compositions for use in treaatment
WO2023187028A1 (en) * 2022-03-31 2023-10-05 Nadavia Holding Aps Mouthwash composition comprising one or more strontium salt
WO2025008636A1 (en) 2023-07-06 2025-01-09 Dentherapy Ltd Oral care compositions for use in the treatment of dental health conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519239A (ja) * 2000-01-07 2003-06-17 アルラ・フーズ・エイ・エム・ビィ・エイ ミルクからのオステオポンチンの単離のための方法
JP2007512379A (ja) * 2003-12-01 2007-05-17 アルラ・フーズ・エイ・エム・ビィ・エイ 歯科用製剤におけるオステオポンチンの使用
WO2009010071A1 (en) * 2007-07-16 2009-01-22 Aarhus Universitet Osteopontin nanoparticles system for drug delivery
JP2009519254A (ja) * 2005-12-16 2009-05-14 アルラ・フーズ・エイ・エム・ビィ・エイ 創傷治癒過程を改善するウシオステオポンチン製剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ507335A (en) 2000-10-05 2004-10-29 New Zealand Dairy Board Bone health compositions derived from milk comprising an acidic protein fraction but that does not contain CGMP
AU2012222312B2 (en) 2011-03-03 2017-06-08 Arla Foods Amba Method for isolating osteopontin using feeds containing cmp or casein species

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519239A (ja) * 2000-01-07 2003-06-17 アルラ・フーズ・エイ・エム・ビィ・エイ ミルクからのオステオポンチンの単離のための方法
JP2007512379A (ja) * 2003-12-01 2007-05-17 アルラ・フーズ・エイ・エム・ビィ・エイ 歯科用製剤におけるオステオポンチンの使用
JP2009519254A (ja) * 2005-12-16 2009-05-14 アルラ・フーズ・エイ・エム・ビィ・エイ 創傷治癒過程を改善するウシオステオポンチン製剤
WO2009010071A1 (en) * 2007-07-16 2009-01-22 Aarhus Universitet Osteopontin nanoparticles system for drug delivery

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021193398A1 (cg-RX-API-DMAC7.html) * 2020-03-27 2021-09-30

Also Published As

Publication number Publication date
US20170065673A1 (en) 2017-03-09
CL2014002583A1 (es) 2015-06-12
CA2868684A1 (en) 2013-10-03
AR090569A1 (es) 2014-11-19
CN104321073A (zh) 2015-01-28
EA201491691A1 (ru) 2015-04-30
KR20150004814A (ko) 2015-01-13
EP2830647A1 (en) 2015-02-04
MX2014011594A (es) 2015-07-06
AU2013241750A8 (en) 2014-10-23
NZ700295A (en) 2016-07-29
US20150044260A1 (en) 2015-02-12
AU2013241750A1 (en) 2014-10-09
WO2013144247A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
US20170065673A1 (en) Nanoparticle aggregates containing osteopontin and calcium- and/or strontium-containing particles
He et al. Polyzwitterion manipulates remineralization and antibiofilm functions against dental demineralization
JP7058344B2 (ja) 歯肉健康を促進するための口腔ケア組成物
Bapat et al. The use of nanoparticles as biomaterials in dentistry
JP7058343B2 (ja) 歯肉健康を促進するための口腔ケア組成物
Zhang et al. Development of a multifunctional adhesive system for prevention of root caries and secondary caries
CN101600442B (zh) 口腔护理产物
RU2404738C2 (ru) Стабилизированные комплексы фосфата кальция
JP7058342B2 (ja) 歯肉健康を促進するための口腔ケア組成物
RU2716134C2 (ru) Стабилизированные композиции на основе олова (II)
JP5973585B2 (ja) ラクトフェリン機能化表面を有する生体模倣ヒドロキシアパタイト粒子を含有するデンタルケア製品
Eshed et al. MgF2 nanoparticle-coated teeth inhibit Streptococcus mutans biofilm formation on a tooth model
KR20190126141A (ko) 치은염을 위한 치료
Babayevska et al. Novel nanosystems to enhance biological activity of hydroxyapatite against dental caries
RU2722306C1 (ru) Композиция для регуляции микроэлементного обмена в полости рта
Xu et al. VMT/ACP/Dextran composite nanosheets against dental caries through promoting mineralization of dentin tubules, pH buffering, and antibacterial
Mu et al. Yellow light and ultrasound Dual-responsive strontium-doped zinc oxide composites for dental caries prevention and remineralization
Wakwak Biomimetic remineralization with nano-hydroxyapatite treatment of enamel erosion (an in vitro study)
Asgartooran et al. Effect of different boron contents within boron-doped hydroxyapatite-chitosan nano-composite on the microhardness of demineralized enamel
El-Gar et al. Potent antibacterial and antibiofilm activities of a synthetic remineralizing preparation of nano-hydroxyapatite against cariogenic Streptococcus mutans using an ex-vivo animal model
Helal et al. Comparing the remineralization potential of undemineralized dentin powder versus chicken eggshell powder on artificially induced initial enamel carious lesions: an in-vitro investigation
US12414904B2 (en) Composition for the remineralization of teeth
Tabari et al. The effect of silicone oil and nano-hydroxyapatite/chitosan powder on microhardness and surface structure of primary teeth enamel after iron drop consumption
CN105287244A (zh) 蒙脱石功能性牙膏及其制备方法
Shakir et al. Innovation of nano-hydrogels loaded with amelogenin peptide and hydroxyapatite nano-particles for remineralisation of artificially induced white spot lesions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170704